The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash.

A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...

AbbVie announced it will acquire Capstan Therapeutics, a startup developing CAR-T therapies for autoimmune conditions, ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

Capstan brings a new modality to AbbVie’s immunology pipeline. The most advanced Capstan program is CPTX2309, which is being developed as a treatment for B cell-mediated autoimmune disorders.

ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.